在脑机接口概念持续火爆的当下，正在经历业绩下行的国产发光五虎之一——亚辉龙（688575.SH）也蠢蠢欲动。 1月6日晚间，亚辉龙公告，公司于近日与深圳脑机星链科技有限公司（以下简称："脑机星链"）签署了《战略合作框架协议》，双方拟通过整合脑机接 口技术与临床和市场资源，共同开发脑机接口相关在研产品及推进后续市场拓展及推广，提升在中枢神经疾病等领域诊疗技术水平。 公告发出3小时后，上交所火速发布问询函，要求亚辉龙补充回应脑机星链主要技术路线、主要产品类型、应用领域、产品所处研发或商业化状态等， 以及说明双方产品在应用领域、客户、渠道等方面的协同性，分析合作开展市场推广的可行性。 同时，上交所还质疑合作存在内幕信息泄露的可能，要求亚辉龙就本次签订框架协议事项进行内幕信息知情人交易情况自查。 1月7日晚间，亚辉龙及有关责任人、英集芯及有关责任人，均被上交所予以监管警示。 2025年前三季度，亚辉龙营业收入12.87 亿元，同比下滑7.69%，净利润6042.09万元，同比下滑72.36%。期间，公司也尝试通过出海，加强市场拓展等 方式低于下行趋势，但目前来看，效果甚微。 去年全年，在A股市场全面走牛，主要指数普遍 ...

Core Viewpoint - The article discusses the recent strategic cooperation between Aihuilong (亚辉龙) and Shenzhen Brain Machine Starlink Technology Co., Ltd. (脑机星链) in the field of brain-computer interface technology, highlighting the challenges and market reactions following the announcement [1][4][10]. Group 1: Company Performance and Market Reaction - Aihuilong has experienced a decline in performance, with a revenue of 1.287 billion yuan for the first three quarters of 2025, down 7.69% year-on-year, and a net profit of 60.42 million yuan, down 72.36% year-on-year [4][5]. - Following the announcement of the cooperation, Aihuilong's stock price initially rose but then fell, with a drop of over 1% on January 8, leading to a total market value of approximately 8.8 billion yuan [2][5]. - The company's stock price decreased by 8.83% over the previous year, despite a bullish A-share market [5]. Group 2: Strategic Cooperation Details - Aihuilong signed a strategic cooperation framework agreement with Brain Machine Starlink to develop brain-computer interface products and enhance diagnostic technologies for central nervous system diseases [1][4]. - The cooperation has raised questions regarding the credibility and technological capabilities of Brain Machine Starlink, which was established only four months prior and has a registered capital of 5 million yuan [5][10]. - Aihuilong clarified that the products under development by Brain Machine Starlink are primarily non-invasive and have not yet entered the registration phase, with some products still in early research or pre-clinical stages [10][12]. Group 3: Regulatory Scrutiny and Information Disclosure - The Shanghai Stock Exchange issued an inquiry to Aihuilong regarding the inconsistency in the disclosure of Brain Machine Starlink's technology path and the lack of detailed information on the cooperation's feasibility and risks [2][11]. - Aihuilong's announcement was criticized for not adequately addressing investor concerns about the collaboration's potential impact on the company's performance and the uncertainty surrounding the partnership [12][13]. - The exchange's inquiry included requests for detailed information on the technological collaboration, product types, and the expected timeline for further agreements [13].

脑机星链成立于2025年9月，注册资本为人民币500万元，成立时间较短，规模较小，目前推进后续的研 发尚需要进一步融资扩大资本规模。亚辉龙称，公司短期内不排除有股权投资、合资等合作安排，但预 计投资金额较小，对公司不会有重大影响。 据公告，亚辉龙拟未来对脑机星链进行投资或支持的形式为股权投资或合资的形式，最终将根据脑机星 链最终确定的融资计划确定，公司根据脑机星链的具体融资计划及估值综合考虑对脑机星链的投资规模 将不超过人民币1500万元。 1月7日晚，上交所科创板公司管理部发布关于亚辉龙及有关责任人予以监管警示的决定称，经查明，亚 辉龙于1月6日收盘后公告披露称，公司与深圳脑机星链科技有限公司(下称脑机星链)签订《战略合作框 架协议》，双方将在产品研发、市场推广以及股权投资等方面开展合作，并称脑机星链是一家以人工智 能为核心驱动力，深耕非侵入式与侵入式双技术路径的企业，已开发脑电采集分析仪等产品。该公告披 露后，引发媒体报道及市场关注。 经上交所督促，亚辉龙于1月6日当晚又发布《关于自愿披露签署战略合作框架协议的补充公告》称，脑 机星链目前在研产品的技术路线为非侵入式技术路径，尚无侵入式技术布局，且脑电采集 ...

长江商报消息 ●长江商报记者 沈右荣 涉足火热的脑机接口领域，亚辉龙（688575.SH）遭交易所闪电问询。 1月6日晚间，亚辉龙发布公告称，近日，公司与深圳脑机星链科技有限公司（以下简称"脑机星链"）签 署了《战略合作框架协议》，通过整合脑机接口技术与临床和市场资源，共同开发脑机接口相关在研产 品及推进后续市场拓展及推广。 亚辉龙在公告中称，此次合作，有利于拓展公司在脑机接口相关领域的战略布局。 亚辉龙还针对上述协议发布补充公告称，脑机星链目前在研产品的技术路线为非侵入式技术路径，与马 斯克创建的脑机接口公司Neuralink在技术路线上存在本质区别，目前也尚无侵入式技术布局。 就在当晚，上交所火速向亚辉龙发出问询函，要求公司补充披露与脑机星链的合作细节，并对脑机星链 商业化合理性、交易双方合作研发可行性、亚辉龙后续投资可行性进行问询。 亚辉龙是一家体外诊断公司，近年来，经营业绩增长承压。2025年前三季度，公司实现的归母净利润为 6042.09万元，同比下降72.36%；期末，公司的应收账款与存货合计达11.71亿元。 交易所连夜发出三连问 亚辉龙蹭热点式布局，引发市场高度关注，上交所连夜发出三连问。 1 ...

（编辑 楚丽君） 证券日报网讯 1月7日，新产业在互动平台回答投资者提问时表示，根据国内医院诊疗结构数据，三级 医院占据了超半数的医院诊疗人次，同时也是体外诊断产品的重要终端用户，因此随着公司超高速发光 仪器MAGLUMI X8、MAGLUMI X10和SATLARS T8 流水线产品获得终端的认可，公司将持续加大对 三级医院等中大型终端的开拓和渗透，提升单机产出。同时，为开拓二级及以下医疗终端市场，公司通 过开发更具性价比的产品MAGLUMI X3和MAGLUMI X6化学发光分析仪器，来满足中小终端对高质 量、高性价比和优质售后服务的化学发光免疫诊断产品的需求，降低医疗终端开支。在海外市场，随着 SNIBE 品牌影响力的持续扩大，中大型机销售占比的持续提升，该比例已由2023年的57%、2024年的 67%，进一步提升至2025年前三季度的76%。未来，公司将更加聚焦于大型机及流水线在全球高端终端 的拓展，推动大样本量客户成为公司持续增长的核心引擎。公司在国内和海外免疫诊断市场领域的市占 率仍处于相对较低水平，这意味着公司在国内外市场仍存在广阔的增长空间。 ...

Core Viewpoint - Aihui Long (688575.SH) announced a strategic cooperation with Shenzhen Brain Machine Starlink Technology Co., Ltd. to explore brain-computer interface technology, which has raised regulatory concerns due to the sudden nature of the announcement and the company's recent poor performance in its core business [2][3][5]. Group 1: Company Announcement and Market Reaction - Aihui Long signed a strategic cooperation framework agreement with Brain Machine Starlink on January 6, focusing on brain-computer interface technology development and commercialization [2]. - Following the announcement, Aihui Long's stock price surged from 14.64 CNY to 15.80 CNY, marking a 6.52% increase with a trading volume up by 299% compared to the previous day [2]. - The Shanghai Stock Exchange issued an inquiry to Aihui Long regarding the feasibility of the cooperation, including questions about the partnership's rationale and potential insider trading [2][5]. Group 2: Financial Performance and Concerns - Aihui Long's financial performance has been declining, with a 7.69% drop in revenue and a 72.36% decrease in net profit for the first three quarters of 2025 [3][6]. - The company is attempting to pivot into the growing brain-computer interface market amid stagnation in its core business of in vitro diagnostic instruments [3]. - The inquiry from the exchange also focused on the reasons behind the significant decline in Aihui Long's financials and the potential impact of the new cooperation on its existing business [6]. Group 3: Details on the Cooperation Partner - Brain Machine Starlink was established only four months prior to the announcement, with a registered capital of 5 million CNY and a focus on comprehensive diagnosis, treatment, and rehabilitation of brain diseases [3][4]. - Both companies share the same registered address in Shenzhen, raising questions about the legitimacy and depth of the partnership [4]. - The products under development by Brain Machine Starlink, including non-invasive brain-computer interface devices, are still in early stages and have not yet entered the registration phase [4].

有投资者在互动平台向新产业提问："尊敬的董秘，您好！请问贵司目前客户拓展的方向，主要是大型 医院？中小医院？还是基层医院？贵司的高端设备产品是否适用于中小医院和基层医院？另外在国外， 譬如东南亚或中东等等贵司已开展业务的区域，哪种规模的医院新增增速更快？当前的国内和国际市场 对于贵司来说，是属于成长期？还是成熟期？谢谢！" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 来源：市场资讯 针对上述提问，新产业回应称："您好，根据国内医院诊疗结构数据，三级医院占据了超半数的医院诊 疗人次，同时也是体外诊断产品的重要终端用户，因此随着公司超高速发光仪器MAGLUMI X8、 MAGLUMI X10和SATLARS T8 流水线产品获得终端的认可，公司将持续加大对三级医院等中大型终端 的开拓和渗透，提升单机产出。同时，为开拓二级及以下医疗终端市场，公司通过开发更具性价比的产 品MAGLUMI X3和MAGLUMI X6化学发光分析仪器，来满足中小终端对高质量、高性价比和优质售后 服务的化学发光免疫诊断产品的需求，降低医疗终端开支。在海外市场，随着 SNIBE 品牌影响力的持 ...

同时，上交所还质疑合作存在内幕信息泄露的可能，要求亚辉龙就本次签订框架协议事项进行内幕信息知情人交易情况自查。 在脑机接口概念持续火爆的当下，正在经历业绩下行的国产发光五虎之一——亚辉龙（688575.SH）也蠢蠢欲动。 1月6日晚间，亚辉龙公告，公司于近日与深圳脑机星链科技有限公司（以下简称："脑机星链"）签署了《战略合作框架协 议》，双方拟通过整合脑机接口技术与临床和市场资源，共同开发脑机接口相关在研产品及推进后续市场拓展及推广，提升在 中枢神经疾病等领域诊疗技术水平。 同时，亚辉龙还承诺利用自身优势及影响力，提升脑机星链的融资及治理优化能力。 值得一提的是，该公告发出之前，亚辉龙白天（1月6日）交易时段股价无缘由大涨6.52%，成交量较上一交易日增长299%。 公告发出三个小时后，上交所火速发布问询函，要求亚辉龙补充回应脑机星链主要技术路线、主要产品类型、应用领域、产品 所处研发或商业化状态等，以及说明双方产品在应用领域、客户、渠道等方面的协同性，分析合作开展市场推广的可行性。 亚辉龙跨界"脑机接口" 作为体外诊断（IVD）领域的新晋龙头，亚辉龙宣布展开脑机接口合作，似乎有些突然。 从2021年科创板上 ...

截至12月31日，利德曼股东户数3.11万，较上期减少3.62%；人均流通股17487股，较上期增加3.76%。 2025年1月-9月，利德曼实现营业收入2.52亿元，同比减少10.49%；归母净利润-713.48万元，同比减少 765.83%。 分红方面，利德曼A股上市后累计派现1.43亿元。近三年，累计派现544.01万元。 1月7日，利德曼盘中下跌2.08%，截至13:44，报7.05元/股，成交5585.48万元，换手率1.44%，总市值 38.35亿元。 资金流向方面，主力资金净流出585.20万元，特大单买入0.00元，占比0.00%，卖出117.76万元，占比 2.11%；大单买入861.43万元，占比15.42%，卖出1328.87万元，占比23.79%。 利德曼今年以来股价涨1.15%，近5个交易日涨1.00%，近20日跌4.21%，近60日跌6.37%。 资料显示，北京利德曼生化股份有限公司位于北京市北京经济技术开发区兴海路5号，成立日期1997年 11月5日，上市日期2012年2月16日，公司主营业务涉及体外诊断试剂(生化、免疫、分子)、诊断仪器、 生物化学原料。主营业务收入构成为：体外 ...

Core Viewpoint - Antu Biology's stock performance shows a slight increase, with a trading volume of 1.11 billion yuan and a net financing buy of 640,600 yuan on January 6, indicating low financing levels compared to historical data [1] Financing Summary - On January 6, Antu Biology had a financing buy of 13.26 million yuan and a financing repayment of 12.62 million yuan, resulting in a net financing buy of 640,600 yuan [1] - The total financing and securities lending balance for Antu Biology reached 463 million yuan, with the financing balance at 459 million yuan, accounting for 2.21% of the circulating market value, which is below the 10th percentile of the past year [1] - The securities lending data shows a repayment of 700 shares and a sale of 600 shares, with a total sale amount of 21,800 yuan, and a securities lending balance of 3.99 million yuan, also below the 50th percentile of the past year [1] Company Performance Summary - As of September 30, Antu Biology had 34,000 shareholders, a decrease of 0.58% from the previous period, with an average of 16,816 circulating shares per shareholder, an increase of 0.58% [2] - For the period from January to September 2025, Antu Biology reported a revenue of 3.13 billion yuan, a year-on-year decrease of 7.48%, and a net profit attributable to shareholders of 860 million yuan, down 10.11% year-on-year [2] - Since its A-share listing, Antu Biology has distributed a total of 4.05 billion yuan in dividends, with 1.79 billion yuan distributed over the past three years [2] Shareholder Structure Summary - As of September 30, 2025, the top ten circulating shareholders of Antu Biology include Zhonggeng Value Pioneer Stock, holding 7.84 million shares, a decrease of 1.42 million shares from the previous period [2] - Hong Kong Central Clearing Limited is the fourth largest shareholder with 7.15 million shares, an increase of 421,430 shares [2] - Other notable changes include a decrease in holdings by Huabao Zhongzheng Medical ETF and an increase in holdings by Dachen Rui Xiang Mixed A and Dachen Competitive Advantage Mixed A [2]